Sophiris Bio Shares Spike to High of $1.80 in Premarket; Co to Present Topsalysin Phase 3 Data from Positive PLUS-1 Study as a Late Breaking Poster During the 111th American Urological Association Annual Meeting on Saturday
Charles Gross